Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (August 2025)
26 slides from Sutro Biopharma's investor presentation, August 2025
Slide 1: Sutro Biopharma
Sutro Biopharma August 2025 NASDAQ: STRO 1 NON CONFIDENTIAL
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than sta
Slide 3: Next-Generation ADCs Designed to Address Critical Treatment Gaps in Oncology
Next-Generation ADCs Designed to Address Critical Treatment Gaps in Oncology Well-capitalized with runway into early 2027; multiple partnership milestone payments expected within 12 months • Harness platform and data-driven insights to drive pipeline of significant commercial opportunities • Invest
Slide 4: ADCs Designed to Engage Hard-to-Reach Targets with Single- and Dual-Payloads
ADCs Designed to Engage Hard-to-Reach Targets with Single- and Dual-Payloads Pursuing complex targets enabled by our proprietary technology, differentiating from conventional ADCs Pursuing Multi-Payload Developing ADCs for Complex, Validated Targets ADCs to Combat Resistance Expressed Across Tumor T
Slide 5: A Leader in Next-Gen ADCs
A Leader in Next-Gen ADCs Pursuing Complex, High-Value Targets Enabled by XpressCF® 5 NON CONFIDENTIAL
Slide 6: Wider Therapeutic Index Achieved with Sutro's Cell-Free ADC Platform
Wider Therapeutic Index Achieved with Sutro’s Cell-Free ADC Platform Key Sutro Technologies to Improve ADCs Outside the Tumor • Linker & payload design • Click chemistry MTD ADC • Site specific conjugation MTD ADC • Antibody engineering TI TI MED ADC Focused R&D Strategy – Make ADCs Better Inside th
Slide 7: Our XpressCF Platform has Unique ADC Performance Capabilities Over Other Topo1 ADC Platforms
Our XpressCF® Platform has Unique ADC Performance Capabilities Over Other Topo1 ADC Platforms Beta-Glu ADC2/ iADC/ Site HT DAR>8 Fc Silent Bispecific Linker Dual LPs iSAC Specific Screening Abbvie AstraZeneca Daiichi Sankyo Dualitybio Genequantum Genmab Gilead Hansoh Hengrui Kelun Lilly Medilink Mer
Slide 8: Cell-Free Approach Enables Industry-Leading ADC Exposure
8 Cell-Free Approach Enables Industry-Leading ADC Exposure Comparison of Exposure Levels in NHPs at Highest Non-Severely Toxic Dose (HNSTD) Levels in DAR Equivalents 6000 STRO-ADC Why does it matter? DAR4 Conjugated PL Exposure [h ug/mL] 5000 STRO-ADC STRO-004 • For ADCs, exposure drives efficacy 40
Slide 9: STRO-004
STRO-004 Potential Best-in-Class Exatecan ADC Targeting TF 9 NON CONFIDENTIAL
Slide 10: STRO-004: Next-Generation TF-Targeting Exatecan/Topo1 ADC with Enhanced Therapeutic Potential
STRO-004: Next-Generation TF-Targeting Exatecan/Topo1 ADC with Enhanced Therapeutic Potential Optimally Designed for Improved Clinical Benefits, Increased Tolerability Leads Enhanced Stability, Potency and Tumor Selectivity to Enhanced Drug Exposure • Exatecan payload: Clinically validated with pote
Slide 11: STRO-004 Demonstrated Reduced Platform and On-target Toxicity
STRO-004 Demonstrated Reduced Platform and On-target Toxicity Due to Site Specific Conjugation and Beta Glu Linker-Payload Technology In Vitro STRO-004 Tolerability Profile vs. Approved aTF ADC Eye Inflammation Skin Toxicities Human Corneal Epithelial Cells Human Keratinocytes STRO-004 (DAR8-exateca
Slide 12: STRO-004 DAR8 Exatecan Achieved Sustained Tumor Regressions in Xenograft Models
STRO-004 DAR8 Exatecan Achieved Sustained Tumor Regressions in Xenograft Models of NSCLC and HNSCC at Low Doses Lung (TF+++) Head and Neck (TF++) H1975 Growth Curves Detroit562 Growth Curves 1500 1500 (mm3)3) (mm33)) 1250 1250 Volume(mm volume(mm 1000 1000 Tumor Volume TumorVolume 750 750 500 500 Tu
Slide 13: STRO-004 Shows Promising Anti-tumor Activity In TF Positive PDX Models
STRO-004 Shows Promising Anti-tumor Activity In TF Positive PDX Models of HNSCC, NSCLC, Esophageal, and Cervical Cancer > 50% of Tumors Responded to STRO-004 at Low Dose STRO-004 Best response vs TF expression 150 Tumor volume change (%) 100 50 0 -50 -100 TF expression 13 NON CONFIDENTIAL
Slide 14: TF is Broadly Expressed Across Multiple Solid Tumor Indications
TF is Broadly Expressed Across Multiple Solid Tumor Indications with High Unmet Need, Presenting Opportunity for Pan-Tumor Targeting TF expression has been associated with poor disease prognosis and increased metastatic properties Tissue Factor-Expressing Cancers Estimate Of Newly-Diagnosed TF+ Pati
Slide 15: STRO-006 (Integrin αvβ6 / ITGB6)
STRO-006 (Integrin αvβ6 / ITGB6) Potential Best-in-Class Integrin-Beta 6 ADC 15 NON CONFIDENTIAL
Slide 16: Complex ITGB6 Biology Requires Advanced Protein Engineering Capabilities
Complex ITGB6 Biology Requires Advanced Protein Engineering Capabilities Integrin Family Integrin αvβ6 Conformations • ITGB6 belongs to integrin family of adhesion proteins, heterodimerizes with alpha-v (αvβ6) • Exists in multiple conformations – makes it a challenging protein to target ITGB6 – Inte
Slide 17: STRO-006 Demonstrated Superior Anti-Tumor Activity Compared to First-Generation ITGB6 ADCs
STRO-006 Demonstrated Superior Anti-Tumor Activity Compared to First-Generation ITGB6 ADCs at Clinically Relevant Dose Levels Head and Neck (ITGB6+) Bladder (ITGB6++) Lung (ITGB6+++) 17 NON CONFIDENTIAL
Slide 18: Emerging Leader in Dual Payload ADCs
Emerging Leader in Dual Payload ADCs 18 NON CONFIDENTIAL
Slide 19: Dual-Payload ADCs: Innovative Method for Delivering Targeted Combination Therapy
Dual-Payload ADCs: Innovative Method for Delivering Targeted Combination Therapy to Overcome Resistance and Delay Progression ADC + Chemo ADC + ADC Dual Payload ADC Potential benefits of a dual- payload ADCs for targeted combination therapy Safety Improved tolerability (Compared to small Through red
Slide 20: Dual-Payload ADCs Have Induced Tumor Regression After Sequential ADC Resistance
Dual-Payload ADCs Have Induced Tumor Regression After Sequential ADC Resistance Mouse Mouse413 413 Mouse 446 Mouse 446 10 mg/kg MTI ADC 10 mg/kg dpADC 10 mg/kg MTI ADC 10 mg/kg dpADC Mice with Enhertu-resistant tumors were switched onto STRO-002 treatment and subsequently onto dual-payload ADC after
Slide 21: Dual-Payload ADCs Have Improved In Vivo Efficacy in an MTI-Resistant CRC Xenograft Model
Dual-Payload ADCs Have Improved In Vivo Efficacy in an MTI-Resistant CRC Xenograft Model HCT-116 Tumor CRC Xenograft Growth Tumor Curves Growth Curve Relative Tumor Volume (%) 1500 1000 500 0 0 10 20 30 40 Days Post Dose Vehicle control Trastuzumab DAR4 MTI (MMAE) ADC (5 mg/kg) Trastuzumab DAR8 Topo
Slide 22: iADC: Dual-Payload ADC Combining Tumor-Targeted Delivery of a Cytotoxin and Immune Stimulator
iADC: Dual-Payload ADC Combining Tumor-Targeted Delivery of a Cytotoxin and Immune Stimulator Strategic Partnership with Astellas to Deliver New Treatment Options for Cold Tumors and Patients Unresponsive to Existing Cancer Immunotherapies Combining a cytotoxin and immune modulator gives potential t
Slide 23: Novel Mechanism of Action Differentiates iADCs from Other Immunotherapies
Novel Mechanism of Action Differentiates iADCs from Other Immunotherapies Sutro iADCs bridge innate and adaptive immunity to provide broad Sutro STING / PD-1 / CAR-T protection in a single molecule ISAC Vaccine iADC TLR PDL-1 Cells Molecule Targeted and Chemo Mixed ADC Ab Biologic Biologic homogeneo
Slide 24: XpressCF Enables Development of Differentiated Dual-Payload ADCs
XpressCF® Enables Development of Differentiated Dual-Payload ADCs, Leveraging Unique Combinations of Validated Targets Dual-Payload ADCs Have the Potential to Become Future Standard of Care Topo1 x Tubulin Topo1 x PARPi Topo1 x IO Selected Indications Selected Indications Selected Indications • NSCL
Slide 25: Pipeline of Next-Generation ADCs Designed to Engage Hard-to-Reach Targets
Pipeline of Next-Generation ADCs Designed to Engage Hard-to-Reach Targets with Single- and Dual-Payloads PHASE 3/ PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2 REGISTRATIONAL PARTNER WHOLLY-OWNED PROGRAMS STRO-004 Tissue Factor ADC Solid Tumors STRO-006 Integrin αvβ6 AD
Slide 26: Sutro Team Comprised of Industry Leaders
Sutro Team Comprised of Industry Leaders Jane Chung, RPh Hans-Peter Gerber, PhD Barbara Leyman, PhD Chief Executive Officer Chief Scientific Officer Chief Business Officer Greg Chow, MBA David Pauling, JD, MA Venkatesh Srinivasan, PhD Chief Financial Officer Chief Administrative Officer and Chief Te
Sutro Biopharma — Investor Presentation (August 2025) on 6ix